Applying our technology

IPAC utilizes our R&D to develop even more products with great potential for success

IC 702

Treatment of bacterial conjunctivitis

IC 702 is a next generation broad-spectrum ocular antibiotic with a unique MOA designed to be highly effective against resistant bacteria. It has a greater potency compared to currently marketed ocular antibiotics. It maintains potency against fluoroquinolone-resistant and multi-drug resistant clinical isolates, including methicillin-resistant staphylococcus aureus (MRSA), by uniquely targeting topoisomerase IV, DNA gyrase, and DNA primase.

Next steps for IC 702

Formulation development with rapid deployment into Phase 2

View other products

IC 805

for ocular pain

IC 265

for the treatment of dry eye